Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD

StatusUnknown
PhaseNot specified
Started

Record status This record was last updated October 13, 2023 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
  2. Start date: Oct 1, 2023 to Nov 1, 2023v3
  3. Eligibility criteria shortened, about 35 wordsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Assiut University
1,667 trials monitored
See 15 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease. 2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.
Trial Details
NCT Number NCT06069076
Lead Sponsor Assiut University
Conditions
(from sponsor)		 Diabetic Kidney Disease
Related terms Diabetic Nephropathies
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov